

SUPPLEMENTARY MATERIAL

Table S1. LTP sensitization profile of gastrointestinal and non-gastrointestinal symptoms groups.

(A)

Sensitization to	GIS-NO	GIS-YES	p-value
Mal d 3 n (%)	120/127 (94.49)	113/118 (95.76)	<i>ns</i>
Jug r 3 n (%)	149/172 (86.63)	128/154 (83.12)	<i>ns</i>
Ara h 9 n (%)	142/163 (87.12)	132/160 (82.50)	<i>ns</i>
Cor a 8 n (%)	130/171 (76.02)	125/157 (79.62)	<i>ns</i>
Tri a 14 n (%)	100/182 (54.95)	91/161 (56.52)	<i>ns</i>

GIS, gastrointestinal symptoms.

(B)

Sensitization to	GIS-NO*	GIS-YES*	p-value
Pru p 3 monosensitized n (%)	4 (44.44)	5 (55.56)	<i>ns</i>
2 LTPs n (%)	4 (40.00)	6 (60.00)	<i>ns</i>
3 LTPs n (%)	3 (33.33)	6 (66.67)	<i>ns</i>
4 LTPs n (%)	7 (33.33)	14 (66.67)	<i>ns</i>
5 LTPs n (%)	24 (53.33)	21 (46.67)	<i>ns</i>
6 LTPs n (%)	51 (50.00)	51 (50.00)	<i>ns</i>

*Analysis performed with the subgroup of 196 patients (n=196/512; 38.30%) with all the sIgE determinations of the following LTPs: Mal d 3, Jug r 3, Ara h 9, Cor a 8, Tri a 14. All patients were also sensitized to Pru p 3 (inclusion criteria).